Prospective sample collection, data collection and analysis for the clinical applicability of immunome profiles in the discrimination and therapy monitoring of COVID-19 patients in different disease stages as well as for the identification and characterization of long-term consequences of a SARS-CoV-2 infection in comparison to patients with a respiratory non-COVID-19 viral infectious disease and healthy controls. - CoVImmun

Fraunhofer ITMP0 个研究点目标入组 200 人开始时间: 2021年2月19日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Inclusion criteria for COVID-19 patients:
•positive testing for SARS-CoV-2 (PCR) or first presentation to the hospital if the test is known to be positive
•Written consent to participate in the study by the patient or, in the case of patients unable to consent, by the legal representative
•Moderate or severe COVID-19 illness according to the WHO classification scheme:
•o Patient group 1: Score 5-7 (severe - very severe)
•o Patient group 2: Score 3 or 4 (moderate - moderate-severe)
•Inclusion criteria for patients with respiratory non-COVID-19 viral infectious disease:
•positive test for a respiratory non-SARS-CoV-2 virus infection or first presentation in hospital if the test is known to be positive
•negative test for SARS-CoV-2 within the last 2 weeks
•Willingness and ability to give consent to participate in the study and clinical examinations and to adhere to the requirements of the study plan
•Moderate to moderately severe respiratory non-COVID-19 viral infectious disease according to the WHO classification scheme:
•o Control group A: Score 3 or 4 (moderate - moderate-severe)

•Exclusion criteria for COVID-19 patients:
•Imprisoned or incapacitated patients
•Severe anemia (Hb <8mg / dl), which does not allow drawing blood regularly
•Exclusion criteria for patients with a respiratory non-COVID-19 viral infectious disease:
•Imprisoned or incapacitated patients
•Severe anemia (Hb <8mg / dl), which does not allow drawing blood regularly

发起方

Fraunhofer ITMP